Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach
PaperCitations, authors & open-access status
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 24 citations, 2021 year and diamond oa status.
24
Citations
2021
Year
diamond
OA Status